TRIM47-facilitated PLK1 stabilization promotes the proliferation of liver cancer cells.
1/5 보강
[BACKGROUND] Liver cancer (LC) remains a leading cause of cancer-related mortality worldwide, with limited therapeutic options for advanced-stage disease.
APA
Xie T, Fan X, et al. (2025). TRIM47-facilitated PLK1 stabilization promotes the proliferation of liver cancer cells.. Cellular oncology (Dordrecht, Netherlands), 49(1), 7. https://doi.org/10.1007/s13402-025-01130-0
MLA
Xie T, et al.. "TRIM47-facilitated PLK1 stabilization promotes the proliferation of liver cancer cells.." Cellular oncology (Dordrecht, Netherlands), vol. 49, no. 1, 2025, pp. 7.
PMID
41460629 ↗
Abstract 한글 요약
[BACKGROUND] Liver cancer (LC) remains a leading cause of cancer-related mortality worldwide, with limited therapeutic options for advanced-stage disease. While tripartite motif-containing 47 (TRIM47), a typical E3 ubiquitin ligase, has been implicated in cancer progression, its precise role in LC pathogenesis remains unclear.
[METHODS] TRIM47 expression in hepatocellular carcinoma (HCC) tissues was analyzed through public databases. Functional assays, including TRIM47 knockdown and overexpression experiments, were performed to investigate its impact on cell proliferation, apoptosis and the cell cycle both in vitro and in vivo. The investigation was conducted using a combination of methodologies, including yeast-two hybrid screening, ubiquitination assays, and signaling pathway analyses, to elucidate the underlying mechanisms. In addition, rescue assays were performed to validate the effect of TRIM47-PLK1 axis on LC growth.
[RESULTS] TRIM47 was significantly elevated in HCC tissues and positively correlated with advanced clinical stage and poor overall survival. Functionally, TRIM47 knockdown suppressed LC cell growth, while its overexpression promoted tumor proliferation. Furthermore, TRIM47 facilitates cell cycle progression by alleviating G2/M phase arrest and inhibits apoptosis in LC cells. Mechanistically, TRIM47 catalyzes K63-linked ubiquitination of polo-like kinase 1 (PLK1), leading to its stabilization and subsequent activation of the NF-κB and MAPK pathways. Clinical validation confirmed a significant positive correlation between TRIM47 and PLK1 expression in human HCC specimens. Importantly, pharmacological inhibition of PLK1 effectively abrogated TRIM47-driven tumor growth in xenograft models.
[CONCLUSION] This study identifies TRIM47 as a critical regulator of LC progression through PLK1 stabilization and proposes the TRIM47-PLK1 axis as a potential therapeutic target for LC treatment.
[SUPPLEMENTARY INFORMATION] The online version contains supplementary material available at 10.1007/s13402-025-01130-0.
[METHODS] TRIM47 expression in hepatocellular carcinoma (HCC) tissues was analyzed through public databases. Functional assays, including TRIM47 knockdown and overexpression experiments, were performed to investigate its impact on cell proliferation, apoptosis and the cell cycle both in vitro and in vivo. The investigation was conducted using a combination of methodologies, including yeast-two hybrid screening, ubiquitination assays, and signaling pathway analyses, to elucidate the underlying mechanisms. In addition, rescue assays were performed to validate the effect of TRIM47-PLK1 axis on LC growth.
[RESULTS] TRIM47 was significantly elevated in HCC tissues and positively correlated with advanced clinical stage and poor overall survival. Functionally, TRIM47 knockdown suppressed LC cell growth, while its overexpression promoted tumor proliferation. Furthermore, TRIM47 facilitates cell cycle progression by alleviating G2/M phase arrest and inhibits apoptosis in LC cells. Mechanistically, TRIM47 catalyzes K63-linked ubiquitination of polo-like kinase 1 (PLK1), leading to its stabilization and subsequent activation of the NF-κB and MAPK pathways. Clinical validation confirmed a significant positive correlation between TRIM47 and PLK1 expression in human HCC specimens. Importantly, pharmacological inhibition of PLK1 effectively abrogated TRIM47-driven tumor growth in xenograft models.
[CONCLUSION] This study identifies TRIM47 as a critical regulator of LC progression through PLK1 stabilization and proposes the TRIM47-PLK1 axis as a potential therapeutic target for LC treatment.
[SUPPLEMENTARY INFORMATION] The online version contains supplementary material available at 10.1007/s13402-025-01130-0.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- Spatial transcriptomics reveals molecular heterogeneity and subtype-specific therapeutic targets in small cell lung cancer.
- Recent advances in infections as risk factors for lymphoma: a review of the effects of viral, bacterial, and fungal infections in lymphoma.
- Reconstruction of Fingertip or Pulp Defects Using the Free Second Toe Tibial Flap With Plantar Vein.
- Horner syndrome as a postoperative complication of thyroid surgery: a systematic review.
- Targeted Intracellular Copper Reservoir Enhances Liver Cancer Immunotherapy.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Raman Spectroscopic Signatures of Hepatic Carcinoma: Progress and Future Prospect.
- Isolation, Antiradical Activity, and Cytotoxicity of Flavonoids From Cunila angustifolia.
- RBM15 Mediated m6A Modification of SRSF1 Inhibits Cuproptosis in Non-Small Cell Lung Cancer by Mediating ATP7B Alternative Splicing.
- The Novel HSF1 Inhibitor NXP800 Exhibits Robust Antitumor Activity in Hepatocellular Carcinoma.
- Decoding the Anti-Tumour Mechanism of ɑ-Solanine: SRC Inhibition and Ferroptosis Induction in Colon Cancer.
- Microfluidic Encapsulation of Sorafenib-Loaded ZIF-8 Nanoparticles in pH-Responsive Alginate Microparticles for Oral Chemotherapy of Hepatocellular Carcinoma.